Who
Tobin Schilke
Chief Financial & Infra. Ofcr.
Company insider
Files Form 4 as: Chief Financial & Infra. Ofcr., Crinetics Pharmaceuticals; CFO, Revance Therapeutics; Chief Financial Officer, Achaogen.
In numbers
- Trades disclosed
- 96
- Buys
- 0
- Sells
- 18
- Bought
- $0
- Sold
- $2.7M
- Companies
- 3
- Companies where not an officer
- 0
- First trade
- 5 Jul 2016
- Last trade
- 1 Sep 2026
- Last filed
- 1 Sep 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 1 Sep 2026filed 1 Sep 2026 | Crinetics PharmaceuticalsBiotechnology | SEC FORM 4 Code D | $676K7,956 at $85.00 | filing |
| 1 Sep 2026filed 1 Sep 2026 | Crinetics PharmaceuticalsBiotechnology | SEC FORM 4 Code D | $6.1M71,471 at $85.00 | filing |
| 1 Sep 2026filed 1 Sep 2026 | Crinetics Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code D | $4.1M80,000 at $51.25 | filing |
| 1 Sep 2026filed 1 Sep 2026 | Crinetics Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code D | $4.1M80,000 at $51.25 | filing |
| 1 Sep 2026filed 1 Sep 2026 | Crinetics Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code D | $2.1M50,000 at $41.21 | filing |
| 1 Sep 2026filed 1 Sep 2026 | Crinetics Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code D | $2.1M50,000 at $41.21 | filing |
| 1 Sep 2026filed 1 Sep 2026 | Crinetics PharmaceuticalsBiotechnology | SEC FORM 4 Code D | $676K7,956 at $85.00 | filing |
| 1 Sep 2026filed 1 Sep 2026 | Crinetics PharmaceuticalsBiotechnology | SEC FORM 4 Code D | $6.1M71,471 at $85.00 | filing |
| 20 Aug 2026filed 24 Aug 2026 | Crinetics PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —471 at $0.00 | filing |
| 20 Aug 2026filed 24 Aug 2026 | Crinetics PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —471 at $0.00 | filing |
| 3 Mar 2026filed 4 Mar 2026 | Crinetics PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $266K6,713 at $39.67 | filing |
| 3 Mar 2026filed 4 Mar 2026 | Crinetics PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $266K6,713 at $39.67 | filing |
| 23 Feb 2026filed 25 Feb 2026 | Crinetics PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —32,000 at $0.00 | filing |
| 23 Feb 2026filed 25 Feb 2026 | Crinetics Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —50,000 at $0.00 | filing |
| 23 Feb 2026filed 25 Feb 2026 | Crinetics Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —50,000 at $0.00 | filing |
| 23 Feb 2026filed 25 Feb 2026 | Crinetics PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —32,000 at $0.00 | filing |
| 10 Mar 2025filed 11 Mar 2025 | Crinetics Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —80,000 at $0.00 | filing |
| 10 Mar 2025filed 11 Mar 2025 | Crinetics PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —52,000 at $0.00 | filing |
| 6 Feb 2025filed 6 Feb 2025 | Revance Therapeutics | SEC FORM 4 Code D | —103,555 | filing |
| 6 Feb 2025filed 6 Feb 2025 | Revance Therapeutics | SEC FORM 4 Code A | —20,883 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.